In their paper, “Connexin43 Mimetic Peptide Improves Retinal Function and Reduces Inflammation in a Light-Damaged Albino Rat Model,” Guo et al promoted neuroretinal survival in a light damage paradigm by blocking the Connexin43 hemichannels. Using the Phoenix MICRON® OCT to examine the structure of the retina at precise retinal locations as shown by the bright
25.03
2021
Therapeutic target for retinal degeneration studied with the Phoenix MICRON® retinal structure and function tools
In their article, “Effect of MMP-9 gene knockout on retinal vascular form and function,” George et al study the effect of knocking out a matrix protein in a mouse model of retinitis pigmentosa using the Phoenix MICRON® platform including OCT, and Ganzfeld ERG. The combination of the Phoenix MICRON® fundus images, OCT revealing the layers,
25.02
2021
A better mouse model of retinal vein occlusion with the Phoenix MICRON® laser and OCT
Retinal vein occlusion is the second most common retinal vascular disorder leading to loss of vision in developed countries (after diabetic retinopathy). A lack of treatment options is partially caused by a lack of effective animal models; most rodent models do not show the essential symptom of cystoid edema and often heal quickly. In their
27.01
2021
Stunning fundus images of GFP-positive cells demonstrate new intravitreal injection technique
In their article, “A Novel Method Combining Vitreous Aspiration and Intravitreal AAV2/8 Injection Results in Retina-Wide Transduction in Adult Mice,” Da Costa et al use the Phoenix MICRON® III imaging platform to take stunning images demonstrating the success of their novel intravitreal injection technique. Gene therapy is a promising treatment option of genetic retinopathies—adeno-associated viruses
18.11
2020
The Phoenix MICRON® IV system and OCT help evaluate promising compounds for treatment of age-related macular degeneration
Age-related macular degeneration affects tens of millions of people worldwide, leading to vision impairment and blindness. Anti-VEGF treatment helps only 25-40% of patients, leaving others with no recourse to this progressive blinding disease. In their article, “Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor,” Choudhary et al explore potential treatment using
28.10
2020
A year-long longitudinal pattern dystrophy fundus study with the Phoenix MICRON® IV imaging platform
In their 2019 paper, “Novel molecular mechanisms for Prph2‐associated pattern dystrophy,” Chakraborty et al use the Phoenix MICRON® IV retinal imaging platform to longitudinally study the effect of a very specific mutation affecting the Peripherin 2 protein. Peripherin 2 is a protein in rods and cones which, if mutated, can lead to retinitis pigmentosa, cone-rod